Abstract
External Beam Radiation Therapy (EBRT) has been the standard of care for breast conservation radiation therapy, in both Invasive Ductal Carcinoma (IDC) and Ductal Carcinoma In Situ (DCIS). Recent data indicates that Interstitial Implant and High Dose Rate (HDR) radiation afterloading compares favorably to EBRT in selected cases of IDC. There is little data regarding HDR in DCIS. Current ASTRO and American Brachytherapy Society Guidelines consider DCIS an investigational category for primary HDR treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
